13F Holdings
中文EN

DNTH Dianthus Therapeutics, Inc. /DE/

Pharmaceutical Preparations · Nasdaq · SEC CIK 1690585 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-67.3%
TTM net income YoY-91.1%
TTM EPS YoY-64.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8,739.3%
Net margin-7,973.3%
FCF margin-6,349.4%
EBITDA margin-8,733.9%

Returns

ROE-38.4%
ROA-35.9%
ROIC (approx.)-36.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets7.1%
Debt / equity0.00x
Current ratio13.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue10.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.04M$6.24M$2.83M——
R&D expense$145.64M$83.11M$32.84M$29.38M$46.77M
SG&A expense$34.33M$24.99M$18.16M$6.74M$27.93M
Operating income-$177.93M-$101.86M-$48.17M-$29.70M-$74.69M
Income tax$0$0$0$0$0
Net income-$162.34M-$84.97M-$43.55M-$28.48M-$71.14M
EBITDA-$177.82M-$101.77M-$48.11M-$29.68M-$72.67M
EPS (basic)-4.20-2.55-8.45-32.57-1.29
EPS (diluted)-4.20-2.55-8.45-32.57-1.29
Dividends declared per share0.000.000.00——
Weighted avg. shares (diluted)38.62M33.31M5.15M874,23454.95M
Balance sheet
Cash & equivalents$51.09M$23.02M$132.39M$15.43M$7.64M
Short-term investments$353.21M$252.45M$41.39M$60.12M$45.28M
Receivables$52,000$0$294,000$4.70M—
Current assets$409.44M$280.90M$177.45M$82.03M$180.69M
PP&E, net$296,000$194,000$185,000$142,000$7.46M
Total assets$530.92M$374.01M$179.41M$83.11M$189.93M
Current liabilities$30.73M$18.45M$9.63M$8.22M$10.86M
Total liabilities$37.52M$21.53M$10.54M$9.45M$17.26M
Shareholders' equity$493.40M$352.48M$168.87M-$44.37M-$17.25M
Shares outstanding43.22M31.12M14.82M875,27958.80M
Cash flow statement
Operating cash flow-$129.06M-$78.18M-$36.86M-$29.07M-$59.53M
Capital expenditure$213,000$105,000$110,000$139,000$1.26M
Free cash flow-$129.27M-$78.28M-$36.97M-$29.21M-$60.80M
Investing cash flow-$122.83M-$286.81M$20.25M-$59.82M$43.43M
Financing cash flow$280.12M$255.62M$133.57M$96.68M$89.60M
Depreciation & amortization$111,000$96,000$67,000$30,000$2.02M
Stock-based compensation$22.79M$12.89M$2.90M$1.52M$10.31M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.